A new option for pain management in rheumatic diseases
Authors:
M. Olejárová
Authors‘ workplace:
Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha
Published in:
Čes. Revmatol., 33, 2025, No. 1, p. 32-37.
Category:
Úvodník
Overview
The fixed-dose combination of naproxen and esomeprazole represents an innovative approach to managing pain and inflammation in patients with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID) with a relatively lower cardiovascular risk, combined with esomeprazole, a proton pump inhibitor, offers an effective and safer therapeutic option, particularly for patients at increased gastrointestinal and cardiovascular risk. Clinical studies have demonstrated that this combination provides comparable efficacy to celecoxib, but with a lower incidence of gastrointestinal adverse events. The combination also offers the benefits of simplified dosing, good tolerability, and a favorable safety profile, all of which contribute to improved patient adherence to long-term therapy. This article summarizes the available clinical data and the practical benefits of this fixed combination therapy.
Keywords:
osteoarthritis treatment – nonsteroidal anti-inflammatory drugs (NSAIDs) – naproxen – naproxen/esomeprazole – rheumatoid arthritis treatment – ankylosing spondylitis treatment – gastrointestinal safety of NSAIDs – cardiovascular safety of NSAIDs
Sources
- Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382(9894): 769–779.
- Hochberg MC, Fort JG, Svensson O, Hwang C, Sostek M. Fixeddose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr Med Res Opin. 2011; 27(6): 1243–1253.
- Dhillon S. Naproxen/esomeprazole fixed-dose combination: for the treatment of arthritic symptoms and to reduce the risk of gastric ulcers. Drugs Aging 2011; 28(3): 237–248.
- Lovell DJ, Dare JA, Francis-Sedlak M, et al. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis. Pediatr Rheumatol. 2018; 16(1): 41.
- Cryer BL, Sostek MB, Fort JG, Svensson O, Hwang C, Hochberg MC. A fixed-dose combination of naproxen and esomeprazole
magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials. Ann Med. 2011; 43(8): 594–605.
- Datto C, Hellmund R, Siddiqui MK. Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses. Open Access Rheumatol. 2013; 5: 1–19.
- Schmidt M, Lamberts M, Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016; 37(13): 1015–1023.
- Vaishnava P. Balancing risk and benefits: Safety of NSAIDs. Dostupné na: https://www.acc.org/latest-in-cardiology/ten- points-to-remember/2016/07/21/14/26/cardiovascular-safe ty-of-nonaspirin-nsaids
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2025 Issue 1
Most read in this issue
- ÚVODNÍK
- Biological and targeted therapy in axial spondyloarthritis: 2024 update
- Subcutaneous belimumab
- Jubilarians of the Czech Society of Rheumatology in 2025